Fevertree Drinks PLC

Fevertree Drinks Plc, together with its subsidiaries, specializes in crafting and distributing premium mixer beverages across the United Kingdom, the United States, Europe, and other international markets. Its diverse product portfolio includes popular options such as Indian, Mediterranean, elderflower, and Clementine tonic waters, as well as ginger beer, ginger ale, and cola distillers. These high-quality drinks are sold under the Fever-Tree brand name primarily to hospitality venues like pubs, bars, and restaurants. The company, which was founded in 2013, was originally incorporated as Fevertree Topco Limited before adopting its current name, Fevertree Drinks Plc, in October 2014. Its headquarters are situated in London, United Kingdom.

Fevertree Drinks PLC trades as FEVR.L on LSE. The company is classified in Consumer Defensive / Beverages - Non-Alcoholic and reports in GBP.

The current profile places the business in Beverages - Non-Alcoholic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £325.00M of revenue and £22.60M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Fevertree Drinks PLC can be compared against peers such as AEP Plantations Plc, A.G. BARR p.l.c., Bakkavor Group plc, C&C Group plc, Greencore Group plc, Hilton Food Group plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £908.68M, beta of 1.12, and return on equity of +10.1%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

FEVR.L currently shows total debt of £3.80M and beta of 1.12. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.fever-tree.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.